Euclidean Capital LLC
- SEC CIK
- 0001825034
- Latest filing
- Aug 14, 2026
Holdings in Q4 2024
Holdings as of Dec 31, 2024, filed Feb 14, 2025. Long positions only; changes compare share counts with Q3 2024.
- Positions
- 11
- −1 vs. Q3 2024
- Portfolio value
- $736.7M
- −$170.0M (−18.8%) vs. Q3 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| SPYSPDR S&P 500 ETF Trust | ETF | 896,254 | $525.3M | 71.3% | −306,550−25.5% | Reduced | History |
| iShares MSCI India ETF46429B598 | ETF | 2,425,144 | $127.7M | 17.3% | 00.0% | Unchanged | – |
| Vanguard Ftse All-World Ex-US Index Fund922042775 | ETF | 1,013,434 | $58.2M | 7.9% | +505,834+99.7% | Added | – |
| ORICOric Pharmaceuticals, Inc. | COM | 989,410 | $7.98M | 1.1% | 00.0% | Unchanged | History |
| FHTXFoghorn Therapeutics Inc. | COM | 1,573,761 | $7.43M | 1.0% | 00.0% | Unchanged | History |
| PMVPPMV Pharmaceuticals, Inc. | COM | 2,627,643 | $3.97M | 0.5% | 00.0% | Unchanged | History |
| ALECAlector, Inc. | COM | 1,307,858 | $2.47M | 0.3% | 00.0% | Unchanged | History |
| TNYATenaya Therapeutics, Inc. | COM | 1,015,705 | $1.45M | 0.2% | 00.0% | Unchanged | History |
| SRZNSurrozen, Inc. | COM NEW | 87,696 | $1.26M | 0.2% | 00.0% | Unchanged | History |
| RAPTRAPT Therapeutics, Inc. | COM | 657,899 | $1.04M | 0.1% | 00.0% | Unchanged | History |
| Surrozen, Inc.86889P117 | *W EXP 08/01/203 | 170,833 | $3.66K | <0.1% | 00.0% | Unchanged | – |
Sold out since Q3 2024 (1)
Positions held at the end of Q3 2024 that are gone from this filing.